Publications by authors named "Satsuki Onitsuka"
Article Synopsis
- The COVID-19 pandemic has driven the search for new antiviral treatments targeting SARS-CoV-2, specifically the 3C-like protease (3CL).
- Researchers developed a new class of covalent inhibitors using chlorofluoroacetamide (CFA) that effectively block the replication of the virus.
- One specific compound demonstrated strong antiviral activity and favorable properties, indicating its potential as a lead candidate for COVID-19 treatment.
The coronavirus disease 2019 (COVID-19) pandemic has necessitated the development of antiviral agents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The main protease (M) is a promising target for COVID-19 treatment. Here, we report an irreversible SARS-CoV-2 M inhibitor possessing chlorofluoroacetamide (CFA) as a warhead for the covalent modification of M.
View Article and Find Full Text PDF